Poster Abstracts • OFID 2017:4 (Suppl 1) • S475 candidate molecule is recombinant human plasma gelsolin (rhu-pGSN), an abundant normal blood protein whose levels fall proportionally with disease severity. Pretreatment with rhu-pGSN has beneficial effects in many pre-clinical models of inflammation and injury, including pneumonia. We evaluated the effects of delaying therapy with rhu-pGSN up to 48 hours after lethal intra-nasal pneumococcal challenge in a mouse model to more closely mimic realistic clinical circumstances.
Background. Cefiderocol (S-649266) is a novel siderophore cephalosporin under development by Shionogi (Osaka, Japan) . Previous studies have demonstrated cefiderocol efficacy against a diverse population of Gram-negative bacteria with MICs ≤ 4 μg/ mL. Our aim was to further define the agent's clinical role by comparing the efficacy of humanized regimens of cefiderocol, FEP, and MEM against a subset of these Gramnegative isolates.
Methods. 15 Gram-negative isolates were studied. MICs were determined by broth microdilution in triplicate, using reference CLSI methods. Pharmacokinetic studies were conducted to reproduce the humanized exposures of cefiderocol 2g q8h (3h inf.), FEP 2g q8h (3h inf.), and MEM 2g q8h (3 hours inf.). Antibiotics were started 2h post thigh inoculation (0h) and continued for 24 hours in immunocompromised mice. Efficacy was determined as the change in log 10 CFU at 24h compared with 0 hour controls.
Results. 8 Enterobacteriaceae, 4 A. baumannii, and 3 P. aeruginosa isolates were studied. Cefiderocol, FEP, and MEM MICs were in the range of 0.12 to 8 μg/mL, ≤0.03 to >64 μg/mL, and ≤0.06 to >64 μg/mL, respectively. Three of the 15 isolates were susceptible to both meropenem and cefepime. All remaining isolates demonstrated in vitro resistance to one or both comparator agents. Cefiderocol was efficacious against all 15 isolates, regardless of FEP or MEM resistance, producing bacterial reductions from 0 hour between 0.89 to 3.04 log 10 CFU. Against FEP and MEM susceptible isolates, cefiderocol treatment resulted in bacterial kill of 2.6 ± 0.5 and 2.1 ± 0.9 log 10 CFU, respectively, similar to that of FEP (2.6 ± 0.5) and MEM (2.2 ± 0.6). Against MEM and FEP resistant isolates, cefiderocol produced a mean (± SD) bacterial reduction of 1.5 ± 0.4 log 10 CFU at 24 hours.
Conclusion. Cefiderocol humanized exposures produced antibacterial efficacy similar to MEM and FEP for susceptible pathogens, while also displaying activity against Enterobacteriaceae, A. baumannii, and P. aeruginosa with phenotypic resistance to the comparator β-lactams. These studies support the potential clinical utility of cefiderocol against these difficult-to-treat multidrug-resistant pathogens. Background. Mucormycosis is a life-threatening infection with high mortality that occurs predominantly in immunocompromised patients. APX001A is an antifungal agent that targets Gwt1, an early step in the conserved glycosylphosphotidyl inositol (GPI) post-translational modification pathway of surface proteins in eukaryotic cells. Inhibition of inositol acylation by APX001A results in pleiotropic effects such as inhibition of maturation of GPI-anchored proteins necessary for growth and virulence and results in lethality. APX001A has in vitro activity against Mucorales. Here we assessed the in vivo activity of APX001A against Rhizopus delemar (MIC = 0.25 µg/mL).
Methods. ICR mice were immunosuppressed with cyclophosphamide (200 mg/kg) and cortisone acetate (500 mg/kg) on days -2, +3, and +8 relative to intratracheal infection with 2.5 x 10 5 cells of R. delemar 99-880. For survival studies, treatment with APX001 (prodrug) at 52, 104, or 156 mg/kg (twice daily, po), was compared with liposomal amphotericin B (LAmB) at 15 mg/kg (once daily, iv). Treatment started on day +1 through day +8 for APX001 and through day +4 for LAmB. Placebo mice received vehicle control. For fungal burden studies, dosing started 8 hours post infection through day +3. Mice were sacrificed on day +4. Survival time, and tissue fungal burden (by qPCR) served as efficacy endpoints.
Results. APX001 treatment at either 52 or 104 mg/kg prolonged survival of mice vs. placebo (n = 20 per arm) (21-day survival of 0% for placebo, 30% for 52 mg/kg, 45% for 104 mg/kg, P < 0.05 by Log Rank test). APX001 at 104 mg/kg was as good as LAmB treatment (21-day survival of LAmB-treated mice [n = 20] =50%). APX001 at 156 mg/kg did not enhance survival vs. placebo. Further, APX001 at 104 mg/kg and LAmB reduced pulmonary and brain fungal burden by ~1 log and 1.5 log vs. placebo, respectively (P < 0.05, by Wilcoxon rank-sum). The 52 and the 156 mg/kg APX001 doses also reduced tissue fungal burden vs. placebo mice (0.5-1.0 log).
Conclusion. APX001 protected immunosuppressed mice from R. delemar infection with efficacy similar to that of LAmB. Higher doses of APX001 were not protective despite lowering fungal burden. Continued investigation of APX001 as a novel antifungal agent against mucormycosis is warranted.
Disclosures Friday, October 6, 2017: 12:30 PM Background. Bacterial cytological profiling accelerates drug discovery efforts by determining the mechanism of action (MOA) of newly developed antibacterial agents. Our goal was to adapt this technology to the identification and study of the MOA of antifungal compounds. Here we explore the utility of Fungal Cytological Profiling (FCP) of C. albicans in revealing changes in morphology over time using for 6 antifungal agents with unique MOA using fluorescently labeled compounds that specifically stain a variety of subcellular structures including DNA and membranes. Included in the analysis was the novel broad spectrum Gwt1 inhibitor APX001A, the active moiety of the prodrug APX001 which is currently in clinical trials for invasive fungal infections.
Methods. The MICs of 6 antifungals vs. C. albicans were determined by CLSI methodology. For FCP, antifungals were added to cultures (1 × 10 5 cells/mL) in RPMI 1640 (buffered with MOPS) at concentrations near MIC: APX001A (0.064 µg/mL); caspofungin (1 µg/mL); fluconazole (2 µg/mL); flucytosine (2 µg/mL); amphotericin B (1 µg/mL) and nikkomycin (3.33 µg/mL) incubated at 35°C with shaking. At 4 hours and 24 hours, treated cultures were stained with various dyes (for 15 minutes), and staining examined under the fluorescence microscope. Dyes included FM 4-64 (membranes), DAPI (DNA), and Sytox Green (cell viability). High-resolution fluorescence microscopy, image analysis and quantitation of cytological parameters (cell length, width, shape, DNA content) were used to create a cytological profile for each growth condition.
